136 related articles for article (PubMed ID: 36748136)
1. [Pathological features and clinicopathological significance of TERT promoter mutation in breast fibroepithelial tumors without definite diagnosis].
Wang JG; Hu YJ; Guan JJ; Liu HY; Bi ZJ; Zhang LX; Liu YX; Xing XM
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):153-159. PubMed ID: 36748136
[No Abstract] [Full Text] [Related]
2. MED12 exon 2 and TERT promoter mutations in primary and recurrent breast fibroepithelial lesions.
Hu Y; Li G; Wang L; Zhang L; Guan J; Wang J
Pathol Int; 2021 Dec; 71(12):814-822. PubMed ID: 34597441
[TBL] [Abstract][Full Text] [Related]
3. Periductal Stromal Tumor of the Breast with a
Anderson B; Marotti JD; Lefferts JA; Muller KE
Int J Surg Pathol; 2023 Dec; 31(8):1626-1631. PubMed ID: 36823780
[TBL] [Abstract][Full Text] [Related]
4. Recurrent challenges in the evaluation of fibroepithelial lesions.
Giri D
Arch Pathol Lab Med; 2009 May; 133(5):713-21. PubMed ID: 19415945
[TBL] [Abstract][Full Text] [Related]
5. Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast.
Tsang JYS; Hui YK; Lee MA; Lacambra M; Ni YB; Cheung SY; Wu C; Kwong A; Tse GMK
Sci Rep; 2018 Mar; 8(1):3881. PubMed ID: 29497099
[TBL] [Abstract][Full Text] [Related]
6. Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature.
Huo L; Gilcrease MZ
Ann Diagn Pathol; 2009 Aug; 13(4):226-32. PubMed ID: 19608080
[TBL] [Abstract][Full Text] [Related]
7. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
8. A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast Fibroepithelial lesions.
Sim Y; Ng GXP; Ng CCY; Rajasegaran V; Wong SF; Liu W; Guan P; Nagarajan S; Ng WY; Thike AA; Lim JCT; Nasir NDBM; Tan VKM; Madhukumar P; Yong WS; Wong CY; Tan BKT; Ong KW; Teh BT; Tan PH
BMC Med Genomics; 2019 Oct; 12(1):142. PubMed ID: 31647027
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.
Yoshida M; Ogawa R; Yoshida H; Maeshima A; Kanai Y; Kinoshita T; Hiraoka N; Sekine S
Br J Cancer; 2015 Oct; 113(8):1244-8. PubMed ID: 26355235
[TBL] [Abstract][Full Text] [Related]
10. Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.
Piscuoglio S; Ng CK; Murray M; Burke KA; Edelweiss M; Geyer FC; Macedo GS; Inagaki A; Papanastasiou AD; Martelotto LG; Marchio C; Lim RS; Ioris RA; Nahar PK; Bruijn ID; Smyth L; Akram M; Ross D; Petrini JH; Norton L; Solit DB; Baselga J; Brogi E; Ladanyi M; Weigelt B; Reis-Filho JS
J Pathol; 2016 Mar; 238(4):508-18. PubMed ID: 26832993
[TBL] [Abstract][Full Text] [Related]
11. Fibroepithelial tumours of the breast-a review.
Lerwill MF; Lee AHS; Tan PH
Virchows Arch; 2022 Jan; 480(1):45-63. PubMed ID: 34505197
[TBL] [Abstract][Full Text] [Related]
12. Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
Ng CCY; Md Nasir ND; Loke BN; Tay TKY; Thike AA; Rajasegaran V; Liu W; Lee JY; Guan P; Lim AH; Chang KTE; Gudi MA; Madhukumar P; Tan BKT; Tan VKM; Wong CY; Yong WS; Ho GH; Ong KW; ; Yip GWC; Bay BH; Tan P; Teh BT; Tan PH
Mod Pathol; 2021 Jul; 34(7):1320-1332. PubMed ID: 33727697
[TBL] [Abstract][Full Text] [Related]
13. A Diagnostic Approach to Fibroepithelial Breast Lesions.
Tan BY; Tan PH
Surg Pathol Clin; 2018 Mar; 11(1):17-42. PubMed ID: 29413655
[TBL] [Abstract][Full Text] [Related]
14. Core needle biopsy diagnosis of fibroepithelial lesions of the breast: a diagnostic challenge.
Li JJX; Tse GM
Pathology; 2020 Oct; 52(6):627-634. PubMed ID: 32771211
[TBL] [Abstract][Full Text] [Related]
15. Fibroepithelial lesions revisited: implications for diagnosis and management.
Tan PH
Mod Pathol; 2021 Jan; 34(Suppl 1):15-37. PubMed ID: 32461622
[TBL] [Abstract][Full Text] [Related]
16. Development of a Management Algorithm for the Diagnosis of Cellular Fibroepithelial Lesions From Core Needle Biopsies.
Jung J; Kang E; Chae SM; Kim H; Park SY; Yun B; Kim SM; Jang M; Kim SW; Kim EK
Int J Surg Pathol; 2018 Dec; 26(8):684-692. PubMed ID: 29774785
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic stromal histomorphology in fibroepithelial breast lesions: a fresh perspective.
Aiyer HM; Jain M; Thomas S; Logani KB
Indian J Pathol Microbiol; 2000 Jan; 43(1):5-12. PubMed ID: 12583412
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors.
Saimura M; Koga K; Anan K; Mitsuyama S; Tamiya S
Breast Cancer; 2018 Jul; 25(4):470-478. PubMed ID: 29460095
[TBL] [Abstract][Full Text] [Related]
19. A five-gene reverse transcription-PCR assay for pre-operative classification of breast fibroepithelial lesions.
Tan WJ; Cima I; Choudhury Y; Wei X; Lim JC; Thike AA; Tan MH; Tan PH
Breast Cancer Res; 2016 Mar; 18(1):31. PubMed ID: 26961242
[TBL] [Abstract][Full Text] [Related]
20. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
